Back in 2006, a company named Synovex Corp. was launched around discoveries by scientists Michael Brenner and David Lee into the role of Cadherin-11 as an adhesive control part of cell-cell interaction. And for several years, the fully virtual discovery firm operated under the radar until a lead clinical asset emerged: an antibody designed to inhibit Cad-11 designated SDP051.